Neumora Therapeutics (NASDAQ:NMRA) Now Covered by Mizuho

Equities research analysts at Mizuho initiated coverage on shares of Neumora Therapeutics (NASDAQ:NMRAGet Free Report) in a note issued to investors on Monday, Benzinga reports. The firm set an “outperform” rating and a $20.00 price target on the stock. Mizuho’s price objective would indicate a potential upside of 95.12% from the company’s current price.

NMRA has been the subject of several other research reports. JPMorgan Chase & Co. lifted their target price on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of Neumora Therapeutics in a report on Thursday, March 28th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.25.

Check Out Our Latest Analysis on NMRA

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA opened at $10.25 on Monday. Neumora Therapeutics has a 12 month low of $8.33 and a 12 month high of $21.00. The company’s fifty day simple moving average is $9.54 and its 200 day simple moving average is $13.31.

Neumora Therapeutics (NASDAQ:NMRAGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.34). Sell-side analysts expect that Neumora Therapeutics will post -1.46 EPS for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD bought a new stake in Neumora Therapeutics in the first quarter valued at approximately $10,354,000. Baker BROS. Advisors LP bought a new stake in shares of Neumora Therapeutics in the 1st quarter valued at $8,715,000. Artal Group S.A. increased its position in shares of Neumora Therapeutics by 14.5% during the first quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock worth $40,206,000 after buying an additional 371,350 shares during the period. Addis & Hill Inc bought a new position in Neumora Therapeutics during the first quarter worth $4,187,000. Finally, Callan Capital LLC acquired a new position in Neumora Therapeutics in the first quarter valued at $2,819,000. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

(Get Free Report)

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Featured Articles

Analyst Recommendations for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.